Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:919-924

This Article
Right arrow Full Text
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by André, P.
Right arrow Articles by Drouet, L. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by André, P.
Right arrow Articles by Drouet, L. O.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:919-924.)
© 1997 American Heart Association, Inc.


Articles

Relative Involvement of GPIb/IX-vWF Axis and GPIIb/IIIa in Thrombus Growth at High Shear Rates in the Guinea Pig

Patrick André; Patricia Hainaud; Claire Bal dit Sollier; Leonard I. Garfinkel; Jacques P. Caen; ; Ludovic O. Drouet

From the INSERM U353 (P.A., L.O.D.); the Institut des Vaisseaux et du Sang (P.A., P.H., C.B. dit S., J.P.C., L.O.D.), Paris, France; and the Biotechnology General Ltd, Rehovot, Israel (L.I.G.).

Correspondence to Patrick André, Institut des Vaisseaux et du Sang, Hôpital Lariboisière, 8 rue Guy Patin, 75475 Paris Cedex 10, France.

Abstract The relative involvement of the glycoprotein (GP) Ib/IX–von Willebrand factor (vWF) axis and GPIIb/IIIa in thrombus growth at high shear rates was assessed and compared by testing the pharmacological effects of VCL, a recombinant GPIb-binding fragment of vWF (residues 504-728), aurintricarboxylic acid (ATA), which binds to the 509-695 disulfide loop of vWF, and lamifiban, a specific synthetic GPIIb/IIIa antagonist. In vivo, their effects were evaluated in guinea pig mesenteric arteries, in a model of a laser-induced cyclic thrombotic process, and ex vivo, at a shear rate of 1800 s-1, in a capillary perfusion chamber model, in which collagen-adherent platelets are exposed to nonanticoagulated guinea pig blood. In vivo, VCL, ATA, and lamifiban administered 2 minutes after intimal injuries stopped thrombus growth, prevented the cyclic thrombotic process, and induced gradual thrombus dissolution. Ex vivo, at 1800 s-1, collagen exposure to untreated blood for 2 minutes, 4 minutes, or two consecutive periods of 2 minutes each resulted in similar platelet adhesion, 56%, 59%, and 61%, respectively, with an average thrombus volume of 6, 19, and 17.5 µm3/µm2, respectively, without any fibrin formation. This indicated that the two consecutive perfusions did not affect the dynamic process of thrombus growth. When collagen-adherent platelets deposited after the first 2-minute perfusion were perfused for 2 minutes with VCL-, ATA-, or lamifiban-treated blood, thrombus growth was prevented and platelet adhesion remained unchanged, but fibrin formation increased on and around the predeposited platelets. These results suggest that both the GPIb/IX-vWF axis and GPIIb/IIIa are involved in in vivo platelet-to-platelet interactions at high shear rates in the guinea pig.


Key Words: thrombus • von Willebrand factor • GPIb/IX • GPIIb/IIIa




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
J. E. Sadler
A new name in thrombosis, ADAMTS13
PNAS, September 3, 2002; 99(18): 11552 - 11554.
[Full Text] [PDF]